Global Drug Eluting Balloons (DEB) Industry Analysis and Market Forecasts27 May 2010 • by Natalie Aster
GlobalData’s report, “Global Drug Eluting Balloons (DEB) Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016” provides key data, information and analysis on the global Drug Eluting Balloons (DEB) market. The report provides market landscape, competitive landscape and market trends information the Drug Eluting Balloons (DEB) market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The Global Drug Eluting Balloons Market Is Expected To Nearly Double Over the Next Seven Years The global Drug Eluting Balloons (DEBs) market was valued at $60m in 2009 and is expected to grow at 10% over the next seven years. The market will be driven by increased adoption by physicians as long term clinical data is released, and as the device is adopted for newer indications such as peripheral vascular disease. Food and Drug Administration (FDA) product approvals over the next two to three years are also expected to boost uptake in the future, since the US is a major interventional cardiology device market. Moreover, since drug eluting balloons fulfill a huge unmet need gap in the market, the adoption is bound to increase as more physicians become aware of the product.
Drug Eluting Balloon’s Potential to Become a Viable Treatment for a Large Number of Indications to Drive the Market Small vessel disease, bifurcated lesions, in-stent restenosis and peripheral vascular disease represent a nearly $2 billion market. In addition, the complications associated with long term antiplatelet therapy such as the risk of bleeding and contraindications limit the use of the current interventions. Also, the associated cost and patient compliance for current treatments open the door for drug eluting balloons to these markets. The unique value proposition of drug eluting balloons – by improving both the safety and efficacy for some indications – has the potential to create a niche market for DEBs. Preliminary clinical trial results suggest that DEBs could become the standard treatment for peripheral vascular disease and complex lesions in the future. For instance, PACCOCATH ISR I and II show significant reductions in binary restenosis as compared to balloon angioplasty. Another study showing the efficacy of DEB for Small Vessel Disease (SVD) showed a binary restenosis rate of just 5.5%. Market experts estimate that DEBs will account for more than 90% of all percutaneous interventions for peripheral vessel diseases in the future.
B Braun, Eurocor and Invatec Dominate Global Drug Eluting Balloons Market B Braun, Eurocor and Invatec are the three leading companies in the drug eluting balloons market and together account for nearly 96% of the total market. B Braun is the market leader with a 60% market share, followed by Eurocor and Invatec with 30% and 6% share respectively. B Braun’s product SeQuent Please currently has the largest number of completed and ongoing clinical trials. Bayer’s PACCOCATH technology has also been successfully demonstrated in animal models. Although Invatec has three approved products, it entered the market only in 2009.